The funding takes Istesso’s latest round to $13m as the company continues clinical trials on an immunometabolic drug licensed from an Aberdeen spinout in 2007.

Istesso, a UK-based immuno-metabolism drug developer with links to University of Aberdeen research, extended its latest funding round to £10m ($13m) on Friday with a £4m ($5.2m) contribution from undisclosed investors.
The additional tranche follows an initial close in December 2018 backed by commercialisation firm IP Group, its fund management division Parkwalk Advisors and venture capital firm Puhua Capital.
Founded in 2017, Istesso is developing treatments for inflammatory autoimmune diseases including rheumatoid arthritis and multiple sclerosis, which…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?